- To determine the prevalence of (pre)cachexia - To determine whether potential biomarkers of pre-cachexia can be identified
ID
Source
Brief title
Condition
- Appetite and general nutritional disorders
- Miscellaneous and site unspecified neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Prevalence of pre-cachexia and cachexia.
Secondary outcome
-The prevalence of pre-cachexia related to tumour type
-Potential biomarkers of pre-cachexia will be investigated
Background summary
Cachexia is a frequently observed syndrome in cancer patients. It reversely
impacts quality of life and is linearly and prognostically related to clinical
outcome but cannot be fully reversed by conventional nutritional therapy. In
contrast to cachexia, pre-cachexia is expected to be a still reversible state
that may respond to nutritional intervention. Recently, an expert-opinion of
pre-cachexia has been put forward that can be used for the early
identification, and subsequently for the early treatment, of pre-cachexia. The
current proposal aims to study the prevalence of pre-cachexia and cachexia, to
identify patient groups at increased risk and to study the association between
pre-cachexia and several biomarkers.
Study objective
- To determine the prevalence of (pre)cachexia
- To determine whether potential biomarkers of pre-cachexia can be identified
Study design
This study is an observational, cross-sectional study.
Study burden and risks
The burden and risks for the participants is light: an interview of at maximum
30 minutes, including 3 small self-administered questionnaires, 2 VAS-scales
and a measurement of body composition. In addition, patients are asked for
extra blood collection of 2 tubes during routinely collected blood in fasted
state to identify potential biomarkers of pre-cachexia and cachexia
De Boelelaan 1117
1007 MB Amsterdam
NL
De Boelelaan 1117
1007 MB Amsterdam
NL
Listed location countries
Age
Inclusion criteria
- Adults (> 18 years);
- Stage III/IV non small cell lung cancer
- Treatment plan: palliative chemotherapy or chemoradiation
Exclusion criteria
-Ascites (for which treatment is necessary) or serious pitting edema;
-Chemotherapy treatment in the past month;
-Not able to speak the Dutch language;
-Pregnancy.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
| Register | ID |
|---|---|
| CCMO | NL37535.029.11 |
| OMON | NL-OMON24155 |